{"id":"W2976695332","doi":"10.1016/j.jaad.2019.09.042","title":"Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","year":2019,"lang":"en","type":"letter","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Biotech; Merck Sharp and Dohme; Janssen Research and Development; National Institutes of Health; LEO Pharma; Novartis; Valeant Pharmaceuticals International; XBiotech; AbbVie; MedImmune; Merck; School of Public Health, University of California Berkeley; Pfizer; Boehringer Ingelheim; Amgen; UCB; Celgene; Ortho Dermatologics; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Post-hoc analysis; Post hoc; Psoriasis; Randomized controlled trial; Internal medicine; Dermatology; Physical therapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04710203,0.001525693,0.005644033,0.00085844,0.0005739715,0.002284565,0.001809374,0.003675984,0.007603181],"category_scores_gemma":[0.1001833,0.0009159406,0.007504196,0.001266834,0.001211855,0.001627348,0.0005669016,0.004807918,0.0008838397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001536709,"about_ca_system_score_gemma":0.002386888,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008404996,"about_ca_topic_score_gemma":0.002375567,"domain_scores_codex":[0.9762762,0.01497581,0.003768279,0.001869794,0.002483858,0.0006260772],"domain_scores_gemma":[0.8834006,0.08389511,0.01603571,0.003353243,0.01186293,0.001452377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3768232,0.0007980211,0.009661432,0.09847116,0.1339246,0.000795772,0.0004748657,0.0005839383,0.004788766,0.001370709,0.2565148,0.1157926],"study_design_scores_gemma":[0.3502308,0.02039578,0.080704,0.019241,0.3321799,0.0008079965,0.0003481257,0.004959544,0.009120461,0.005672351,0.1756924,0.0006477079],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1619131,0.3508582,0.007135789,0.2413999,0.2012355,0.007989476,0.02155033,0.0009189661,0.006998857],"genre_scores_gemma":[0.5679508,0.05244704,0.01041595,0.179134,0.1665898,0.006137606,0.004243734,0.0007009219,0.01238018],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.04710203,"threshold_uncertainty_score":0.2491024,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01038405607427561,"score_gpt":0.2707176730518084,"score_spread":0.2603336169775328,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}